ID   MIC
AC   CVCL_EI96
DR   cancercelllines; CVCL_EI96
DR   Cosmic; 2250464
DR   GEO; GSM5359676
DR   GEO; GSM5359677
DR   GEO; GSM5359678
DR   GEO; GSM5359679
DR   GEO; GSM5359680
DR   GEO; GSM5359681
DR   GEO; GSM5362930
DR   GEO; GSM5362931
DR   GEO; GSM5362932
DR   GEO; GSM5362933
DR   GEO; GSM5362934
DR   GEO; GSM5362935
DR   GEO; GSM5363981
DR   GEO; GSM5363982
DR   GEO; GSM5363983
DR   GEO; GSM5363984
DR   GEO; GSM5363985
DR   Wikidata; Q54905684
RX   DOI=10.5282/edoc.27750;
RX   PubMed=25223734;
RX   PubMed=36476851;
WW   Info; ESCLA; -; https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?option=about_dscope
CC   Part of: Ewing Sarcoma Cell Line Atlas (ESCLA).
CC   From: Delattre, Olivier; Institut Curie; Paris; France.
CC   Sequence variation: Gene fusion; HGNC; HGNC:3508; EWSR1 + HGNC; HGNC:3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=36476851).
CC   Sequence variation: Mutation; HGNC; HGNC:11355; STAG2; Simple; p.Arg216Ter (c.646C>T); Zygosity=Unspecified (PubMed=25223734).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=25223734).
CC   Omics: Genomics; ChIP-seq; FLI1.
CC   Omics: Genomics; ChIP-seq; H3K27ac.
CC   Omics: Genomics; ChIP-seq; H3K27me3.
CC   Omics: Genomics; ChIP-seq; H3K4me3.
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Proteomics.
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 10-04-25; Version: 11
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622; PMCID=PMC4264969;
RA   Tirode F., Surdez D., Ma X.-T., Parker M., Le Deley M.-C., Bahrami A.,
RA   Zhang Z.-J., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S.,
RA   Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O.,
RA   Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M.,
RA   Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V.,
RA   Michon J., Marec-Berard P., Gut I.G., Downing J.R., Dyer M.A.,
RA   Zhang J.-H., Delattre O.;
RG   International Cancer Genome Consortium;
RG   St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project;
RT   "Genomic landscape of Ewing sarcoma defines an aggressive subtype with
RT   co-association of STAG2 and TP53 mutations.";
RL   Cancer Discov. 4:1342-1353(2014).
//
RX   PubMed=36476851; DOI=10.1016/j.celrep.2022.111761; PMCID=PMC10333306;
RA   Orth M.F., Surdez D., Faehling T., Ehlers A.C., Marchetto A.,
RA   Grossetete-Lalami S., Volckmann R., Zwijnenburg D.A., Gerke J.S., Zaidi S.,
RA   Alonso J., Sastre A., Baulande S., Sill M., Cidre-Aranaz F., Ohmura S.,
RA   Kirchner T., Hauck S.M., Reischl E., Gymrek M., Pfister S.M., Strauch K.,
RA   Koster J., Delattre O., Grunewald T.G.P.;
RT   "Systematic multi-omics cell line profiling uncovers principles of
RT   Ewing sarcoma fusion oncogene-mediated gene regulation.";
RL   Cell Rep. 41:111761.1-111761.28(2022).
//